Posted in Clinical Data Sarepta sees early success with RNAi drugs from Arrowhead March 25, 2026 BioPharma Dive Long-awaited results from Phase 1/2 studies lifted Sarepta s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions. Clinical DataRare DiseaseRead full story